<?xml version="1.0" encoding="UTF-8"?>
<results title="drugs">
 <result pre="14, 15]. These drugs provide longer durations of action. Further," exact="danazol" post="and minocycline (oral medications) and loteprednol (modified topical drugs)"/>
 <result pre="These drugs provide longer durations of action. Further, danazol and" exact="minocycline" post="(oral medications) and loteprednol (modified topical drugs) require daily"/>
 <result pre="durations of action. Further, danazol and minocycline (oral medications) and" exact="loteprednol" post="(modified topical drugs) require daily administration, thus decreasing the"/>
 <result pre="the condition of best-corrected visual acuity (BCVA) [ 28]. Intravitreal" exact="triamcinolone" post="acetonide (IVTA) has been reported to have potent anti-inflammatory"/>
 <result pre="One of such delivery systems for use in DME is" exact="triamcinolone" post="acetonide (TA) implant (I-vation®). I-vation is currently completed in"/>
 <result pre="nonbiodegradable devices [ 37]. Another sustained drug delivery system is" exact="fluocinolone acetonide" post="nonbiodegradable intravitreal insert (Iluvien®, Alimera Sciences). Iluvien is designed"/>
 <result pre="its application to the market [ 13]. In comparison, another" exact="fluocinolone acetonide" post="intravitreal implant, Retisert® (Bausch and Lomb), is approved by"/>
 <result pre="approved Ozurdex (allergen), which is a sustained release of biodegradable" exact="dexamethasone" post="intravitreal implant for the treatment of macular edema. A"/>
 <result pre="that carried out in 2007 discovered that higher dose of" exact="dexamethasone" post="(700  μg) statistically improved that BCVA and well-tolerated by"/>
 <result pre="25  μl dose was incorporated with a lower dose of" exact="triamcinolone" post="(6.9 mg) while 50  μl doses administered with a higher"/>
 <result pre="while 50  μl doses administered with a higher dose of" exact="triamcinolone" post="(13.8 mg) [ 44]. The results showed that the patients"/>
 <result pre="Verisome without any related adverse effects. The lower dose of" exact="triamcinolone" post="showed evidence of controlled release efficacy, with greater control"/>
 <result pre="FDA to treat DR and DME. One of them is" exact="nepafenac" post="(Nevanac®, Alcon), which is a topical nonsteroidal drug that"/>
 <result pre="has shown great efficacy to treat DME [ 45]. However," exact="nepafenac" post="testing in clinical trials is under way. Next, etanercept"/>
 <result pre="However, nepafenac testing in clinical trials is under way. Next," exact="etanercept" post="(Enbrel®, Amgen Inc., and Wyeth) is a recombinant fusion"/>
 <result pre="has shown that patients with refractory DME treated with intravitreal" exact="etanercept" post="did not show any improvements [ 47]. Another, TNF-"/>
 <result pre="show any improvements [ 47]. Another, TNF- α antagonist is" exact="infliximab" post="(Remicade®, Centocor) and it is used to treat Crohn's"/>
 <result pre="to treat Crohn's disease. Systemic treatment of DME with intravitreal" exact="infliximab" post="injection achieved anatomic and functional improvement was achieved ["/>
 <result pre="with PDR [ 55, 56]. In 2006, FDA has approved" exact="ranibizumab" post="(Lucentis®, Genentech Inc.), which is a recombinant humanized antibody"/>
 <result pre="I study [ 65]. Lastly, an orally administered antiangiogenic drug," exact="pazopanib" post="was developed by GlaxoSmithKline. This drug is designed to"/>
 <result pre="cholesterol. The results obtained from the FIELD study suggested that" exact="fenofibrate" post="is a potential adjunct to photocoagulation. Besides, the effect"/>
 <result pre="is a potential adjunct to photocoagulation. Besides, the effect of" exact="fenofibrate" post="also acts via nonlipidemic mechanisms, mainly activating PPAR- α"/>
 <result pre="α for DR prevention. Activation of PPAR- α mediated by" exact="fenofibrate" post="led to inhibition of VEGFR2 expression and neovascularization in"/>
 <result pre="VEGFR2 expression and neovascularization in human umbilical endothelial cells. Moreover," exact="fenofibrate" post="also activates PPAR α to induce the expression of"/>
 <result pre="on neuron cells [ 78– 80]. 4.8.2. Statins Treatment of" exact="atorvastatin" post="alone has been shown to be ineffective in reducing"/>
 <result pre="Diabetes Study (CARDS) [ 81]. Besides, the contemporary therapy between" exact="fenofibrate" post="and atorvastatin was carried by ACCORD-Eye sub study by"/>
 <result pre="(CARDS) [ 81]. Besides, the contemporary therapy between fenofibrate and" exact="atorvastatin" post="was carried by ACCORD-Eye sub study by using a"/>
 <result pre="the rate of DR progression was seen after treatment with" exact="enalapril" post="and losartan, respectively [ 84]. 4.9.2. Angiotensin-2 Receptor Blockers"/>
 <result pre="2 diabetic patients with DR. DIRECT-Prevent1 and DIRECT-Protect1 revealed that" exact="candesartan" post="cannot prevent DR progression while no significant reduction in"/>
 <result pre="progression of DR was found in DIRECT-Protect2. Despite this fact," exact="candesartan" post="could treat patients with mild DR [ 85]. 4.9.3."/>
 <result pre="the progression of DR was observed when it used with" exact="dipyridamole" post="[ 86, 87]. Moreover, Dipyridamole, Aspirin, Microangiopathy of Diabetes"/>
 <result pre="(DAMAD) study further showed that combination use of aspirin and" exact="dipyridamole" post="caused a significant reduction in microaneurysms formation [ 86]."/>
 <result pre="functions to reduce glucose in the retina to sorbitol using" exact="nicotinamide" post="adenine dinucleotide phosphate (NADPH) as a cofactor [ 94,"/>
 <result pre="Schwartz S. D. Severe steroid-induced glaucoma following intravitreal injection of" exact="triamcinolone" post="acetonide American Journal of Ophthalmology 2006 141 3 580"/>
 <result pre="Simpson J. M. Larsson J. Ali H. Zhu M. Intravitreal" exact="triamcinolone" post="for refractory diabetic macular edema: two-year results of a"/>
 <result pre="Morescalchi F. Gandolfo F. et al. Clinical evidence of intravitreal" exact="triamcinolone" post="acetonide in the management of age-related macular degeneration Current"/>
 <result pre="D. S. Chan C. K. Mohamed S. et al. Intravitreal" exact="triamcinolone" post="plus sequential grid laser versus triamcinolone or laser alone"/>
 <result pre="S. et al. Intravitreal triamcinolone plus sequential grid laser versus" exact="triamcinolone" post="or laser alone for treating diabetic macular edema: six-month"/>
 <result pre="M. Anisian A. A randomized, placebo-controlled clinical trial of intravitreal" exact="triamcinolone" post="for refractory diabetic macular edema International Ophthalmology 2008 28"/>
 <result pre="S. Glassman A. R. The risk of endophthalmitis following intravitreal" exact="triamcinolone" post="injection in the DRCRnet and SCORE clinical trials American"/>
 <result pre="T. Weaver C. D. Gallagher M. J. et al. Intravitreal" exact="triamcinolone" post="acetonide injection for treatment of refractory diabetic macular edema:"/>
 <result pre="J. A. et al. Randomized controlled study of an intravitreous" exact="dexamethasone" post="drug delivery system in patients with persistent macular edema"/>
 <result pre="M. S. et al. Randomized controlled trial of an intravitreous" exact="dexamethasone" post="drug delivery system in patients with diabetic macular edema"/>
 <result pre="G. Warren K. Cystoid and diabetic macular edema treated with" exact="nepafenac" post="0.1% Journal of Ocular Pharmacology and Therapeutics 2007 23"/>
 <result pre="A. Krikonis T. S. Christodoulakis E. The use of intravitreal" exact="etanercept" post="in diabetic macular oedema Seminars in Ophthalmology 2007 22"/>
 <result pre="diabetes following treatment with the anti-tumor necrosis factor monoclonal antibody" exact="infliximab" post="Diabetes Care 2005 28 2 445 447 10.2337/diacare.28.2.445 15677814"/>
 <result pre="Puliafito C. A. Marcus E. N. Venkatraman A. S. Systemic" exact="bevacizumab" post="(Avastin) therapy for neovascular age-related macular degeneration: twelve-week results"/>
 <result pre="D. Spaide R. F. Meyerle C. B. et al. Intravitreal" exact="bevacizumab" post="(Avastin) treatment of macular edema in central retinal vein"/>
 <result pre="R. L. Pearlman J. Pieramici D. J. et al. Intravitreal" exact="bevacizumab" post="(Avastin) in the treatment of proliferative diabetic retinopathy Ophthalmology"/>
 <result pre="Maar N. Bolz M. Scholda C. Schmidt-Erfurth U. Repeated intravitreal" exact="bevacizumab" post="(Avastin®) treatment of persistent new vessels in proliferative diabetic"/>
 <result pre="Kusuhara S. Tsukahara Y. Negi A. Early responses to intravitreal" exact="ranibizumab" post="in typical neovascular age-related macular degeneration and polypoidal choroidal"/>
 <result pre="and regression of choroidal neovascularization by the multitargeted kinase inhibitor" exact="pazopanib" post="Archives of Ophthalmology 2009 127 4 494 499 10.1001/archophthalmol.2009.27"/>
 <result pre="III trials of an intravitreous injection of highly purified ovine" exact="hyaluronidase" post="(Vitrase®) for the management of vitreous hemorrhage American Journal"/>
 <result pre="H. et al. Phase I study of 30-minute infusion of" exact="carfilzomib" post="as single agent or in combination with low-dose dexamethasone"/>
 <result pre="of carfilzomib as single agent or in combination with low-dose" exact="dexamethasone" post="in patients with relapsed and/or refractory multiple myeloma Journal"/>
 <result pre="18541841 76 Nagi D. K. Yudkin J. S. Effects of" exact="metformin" post="on insulin resistance, risk factors for cardiovascular disease, and"/>
 <result pre="B. Gardiner R. et al. Renal and retinal effects of" exact="enalapril" post="and losartan in type 1 diabetes The New England"/>
 <result pre="R. et al. Renal and retinal effects of enalapril and" exact="losartan" post="in type 1 diabetes The New England Journal of"/>
 <result pre="Chaturvedi N. Porta M. Klein R. et al. Effect of" exact="candesartan" post="on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of"/>
 <result pre="DAMAD Study Group Effect of aspirin alone and aspirin plus" exact="dipyridamole" post="in early diabetic retinopathy. A multicenter randomized controlled clinical"/>
</results>
